Published in PLoS Pathog on June 23, 2016
Immune history and influenza virus susceptibility. Curr Opin Virol (2017) 0.76
Epitope-Specific Suppression of IgG Responses by Passively Administered Specific IgG: Evidence of Epitope Masking. Front Immunol (2017) 0.75
IgG3-antigen complexes are deposited on follicular dendritic cells in the presence of C1q and C3. Sci Rep (2017) 0.75
Evolution and ecology of influenza A viruses. Microbiol Rev (1992) 39.99
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis (2011) 14.93
The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine (2007) 9.96
Humoral immunity due to long-lived plasma cells. Immunity (1998) 6.35
Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis (2007) 5.91
Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science (2010) 5.13
Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest (2010) 4.62
Kinetics of influenza A virus infection in humans. J Virol (2006) 3.78
Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc Natl Acad Sci U S A (2010) 2.59
The biology of influenza viruses. Vaccine (2008) 2.58
Strategies for pandemic and seasonal influenza vaccination of schoolchildren in the United States. Am J Epidemiol (2009) 2.47
The current status of the control of influenza. Ann Intern Med (1955) 2.38
A soluble domain of the membrane-anchoring chain of influenza virus hemagglutinin (HA2) folds in Escherichia coli into the low-pH-induced conformation. Proc Natl Acad Sci U S A (1995) 2.24
Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol (2013) 2.09
Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature (2013) 2.08
Estimating influenza vaccine efficacy from challenge and community-based study data. Am J Epidemiol (2008) 2.07
Antibody landscapes after influenza virus infection or vaccination. Science (2014) 2.04
Heterosubtypic immunity to influenza A virus: where do we stand? Microbes Infect (2008) 1.88
A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science (2015) 1.87
Antibody-mediated modulation of immune responses. Immunol Rev (2010) 1.84
Quantifying the early immune response and adaptive immune response kinetics in mice infected with influenza A virus. J Virol (2010) 1.80
Simulation and prediction of the adaptive immune response to influenza A virus infection. J Virol (2009) 1.76
Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat Med (2015) 1.74
Dynamics of influenza virus infection and pathology. J Virol (2010) 1.62
Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. J Virol (2013) 1.49
Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans. Proc Natl Acad Sci U S A (2014) 1.49
Quantitative relationships between an influenza virus and neutralizing antibody. Virology (1987) 1.37
Germinal center B cells govern their own fate via antibody feedback. J Exp Med (2013) 1.36
Electron microscopy of influenza virus. Br Med Bull (1979) 1.32
Evidence for antigenic seniority in influenza A (H3N2) antibody responses in southern China. PLoS Pathog (2012) 1.32
Differential neutralization efficiency of hemagglutinin epitopes, antibody interference, and the design of influenza vaccines. Proc Natl Acad Sci U S A (2009) 1.31
Modeling within-host dynamics of influenza virus infection including immune responses. PLoS Comput Biol (2012) 1.26
Influenza virus still surprises. Curr Opin Microbiol (2002) 1.16
H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge. J Virol (2013) 1.14
Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant. J Infect Dis (2011) 1.08
Immune history profoundly affects broadly protective B cell responses to influenza. Sci Transl Med (2015) 1.06
How can vaccines against influenza and other viral diseases be made more effective? PLoS Biol (2010) 0.96
Modeling of influenza-specific CD8+ T cells during the primary response indicates that the spleen is a major source of effectors. J Immunol (2011) 0.95
Immune response modeling of interferon beta-pretreated influenza virus-infected human dendritic cells. Biophys J (2010) 0.93
Toward quantitative simulation of germinal center dynamics: biological and modeling insights from experimental validation. J Theor Biol (2001) 0.87
Estimating the life course of influenza A(H3N2) antibody responses from cross-sectional data. PLoS Biol (2015) 0.86
Estimating the effect of influenza vaccines. Lancet Infect Dis (2011) 0.81
Exploring the mechanisms of primary antibody responses to T cell-dependent antigens. J Theor Biol (1996) 0.80
Masking of antigenic epitopes by antibodies shapes the humoral immune response to influenza. Philos Trans R Soc Lond B Biol Sci (2015) 0.77
Model of influenza A virus infection: dynamics of viral antagonism and innate immune response. J Theor Biol (2014) 0.77